Bleeding After Menopause With a Normal Uterus: Vaginal Cancer
Bleeding after menopause has one default suspect. The uterus. The workup goes there first, and that order is right, because that is where the common cancer is. Then the sampling comes back benign. Or the lining measures thin. Or there is no uterus at all, taken out years ago for something unrelated. The bleeding has not stopped. Something is still producing it, and the question of what has only got narrower. Looking for the source after the obvious organ has been cleared is the discipline Healz was built on.
This post stays with that second question. How uncommon primary vaginal cancer is, and why cancer found in the vagina often did not begin there. The HPV link and the precursor before invasion. The part of the examination where a lesion hides in plain sight. And why the treatment here is built around radiation.

Why the uterus is checked first, and what a normal result leaves open
Postmenopausal bleeding moves endometrial cancer to the front of the queue, and it belongs there. Most of the time the answer is in the uterus or the thinned tissue around it, which is why the first tests point there. Our piece on what an endometrial biopsy can and cannot settle walks that path in detail.
The gap opens once the endometrium is cleared. A benign sampling result is a statement about the tissue that was sampled, nothing more. Blood arriving from the vaginal wall, the vulva, the cervix, the urethra or the rectum was never in that specimen.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
After a hysterectomy there is no endometrium to sample, so the commonest explanation is gone from the start. NCI's PDQ treatment summary for vaginal cancer lists a history of hysterectomy among the risk factors, alongside HPV infection and exposure to diethylstilbestrol before birth. The operation that removes the usual suspect sits on the risk list for the unusual one.
The geography matches. In a retrospective series of 100 women studied over 30 years, cited in that NCI summary, half had undergone a hysterectomy. In that group, 31 of 50 (62%) developed cancers limited to the upper third of the vagina; among those who had not previously undergone hysterectomy, upper vaginal lesions were found in 17 of 50 (34%). NCI also notes that vaginal carcinoma in situ commonly occurs in the vaginal vault, the surface left at the top when the uterus is removed.
What grows in the vagina, and where most of it came from
NCI describes carcinomas of the vagina as uncommon tumours comprising about 2% of the cancers that arise in the female genital system.
More useful for a bleeding workup: cancer found in the vagina often did not start there. The American Cancer Society writes that cancers found in the vagina often start in other organs, such as the cervix, uterus, rectum or bladder, and then spread to the vagina, and that this is much more common than having vaginal cancer, which starts in the vagina.
Classification then follows anatomy rather than the order of discovery. NCI states that the AJCC staging system classifies tumours in the vagina that involve the cervix of women with an intact uterus as cervical cancers, and that tumours which originated in the apical vagina but extend to the cervix are therefore classified as cervical.
Among the cancers that are genuinely vaginal, squamous cell carcinoma accounts for approximately 80% to 90% of cases, per NCI. Adenocarcinoma is far less common, and one rare form, clear cell carcinoma, occurs in association with in-utero DES exposure, with a peak incidence before age 30. NCI calls that subtype extremely rare now.
HPV runs underneath most of the rest. Cetin and Birge write that HPV infection is thought to be the cause of the majority of vaginal cancer cases. NCI describes vaginal intraepithelial neoplasia, the precursor lesion, as associated with a high rate of HPV infection and thought to have an aetiology similar to cervical intraepithelial neoplasia. The vulva sits in the same HPV neighbourhood and announces itself differently, with an itch rather than bleeding, which our piece on a vulvar itch that will not settle covers.
Symptoms are quiet early and then unspecific. NCI's patient summary says vaginal cancer often does not cause early signs or symptoms. The American Cancer Society lists abnormal bleeding, abnormal discharge, a mass or lump that can be felt and pain during sex, and notes that vaginal cancers may be found on routine pelvic exams or screening.
The part of the examination the speculum hides
A share of missed lesions has nothing to do with how carefully anyone looked.
The Global Library of Women's Medicine chapter on vaginal cancer, by Kushner, puts a number on it: Frick and coworkers reported that at least 19% of cases are missed on initial examination. A small lesion low in the vagina may be covered by the blades of the speculum if it is not rotated to visualise the anterior and posterior walls. The device that opens the vagina for inspection is also covering two of its four walls.
Cetin and Birge add the other half of the manoeuvre: the tumour may be missed unless the vagina is examined as the speculum is removed, or the lesion is palpated on bimanual examination.
What confirms a lesion is colposcopy with biopsy. Cetin and Birge recommend detailed colposcopic examination of any lesion, visible or not, and biopsy of any abnormal site or mass. The American Cancer Society is blunt about why tissue is unavoidable: a biopsy is the only way to know whether an abnormal finding, such as a mass or ulcer, is cancer. NCI adds that if the cervix is intact, biopsies are mandatory to rule out a primary carcinoma of the cervix.
What the staging measures, and what it cannot
NCI states that the FIGO system is the most commonly used staging system for vaginal cancer, and the stages map how far the tumour has pushed outwards: stage I, the carcinoma is limited to the vaginal wall; stage II, it has involved the subvaginal tissue but has not extended to the pelvic wall; stage III, it has extended to the pelvic wall; stage IVa, tumour invades bladder and/or rectal mucosa and/or direct extension beyond the true pelvis; stage IVb, spread to distant organs.
Imaging fills that in. The American Cancer Society says MRI images are useful for showing the exact location and size of the vaginal tumour as well as any enlarged lymph nodes in the groin, CT might be used to see whether cancer has spread to other organs, and a PET scan can find out whether cancer has spread, though PET is not often used in early disease. Cetin and Birge add that FDG-PET can assess primary vaginal tumours and abnormal lymph nodes.
The stage is not the whole prognostic picture. NCI states that prognosis depends primarily on stage, then lists features associated with reduced survival: age over 60 years, symptoms at the time of diagnosis, lesions of the middle and lower third of the vagina, and poorly differentiated tumours.
Why the treatment is built around radiation
Surgery is the reflex expectation for a solid tumour. Here it is the exception. For stage I disease NCI lists both radiation therapy and surgery as treatment options, with the choice turning on histology and lesion thickness; for stage I adenocarcinoma, total radical vaginectomy and hysterectomy with lymph node dissection are indicated because the tumour spreads subepithelially. For stages II, III and IVa, NCI says radiation therapy is the most common treatment, given as external-beam radiation alone or with interstitial or intracavitary brachytherapy.
Brachytherapy delivers radiation from a source placed inside or next to the tumour rather than from outside. NCI notes that intracavitary brachytherapy provides insufficient dose penetration for locally advanced tumours, so interstitial brachytherapy is used when brachytherapy is given. NCI describes external-beam radiation followed by an interstitial and/or intracavitary implant for a total tumour dose of 75 Gy to 80 Gy. Cetin and Birge add that brachytherapy should follow immediately after external radiation is completed.
Chemotherapy enters as an addition rather than the backbone. NCI says concurrent chemotherapy using fluorouracil or cisplatin-based therapy with radiation is sometimes advocated, based solely on extrapolation from cervical cancer management strategies. For stage IVb or recurrent disease that cannot be managed with local treatments, NCI states plainly that current therapy is inadequate. Surgery, when used, is radical vaginectomy or pelvic exenteration, and for stage IVb the listed approach is palliative radiation with or without chemotherapy. Borrowed evidence and an uncommon disease mean the plan rests on judgement as much as protocol, which is exactly when people ask for a second opinion.
How Healz reads a case where the obvious organ came back clean
The examination findings, the biopsy wording and the imaging report are three parts of one case, and they usually arrive as three letters weeks apart. Healz holds them in one chat with the dates attached, not ten apps and three portals.
Healz is equipped with Frontier AI, so the case is worked whole. The note that the walls were inspected on withdrawal reads against the biopsy that followed, and the histology line reads against the staging images. A cancer ai that will read a pathology report in full context treats "squamous cell carcinoma" and "middle third of the vagina" as two facts about one tumour.
Healz is equipped with root-cause technology, so it does not stop at the first label. It asks the questions a rushed visit skips and cross-checks the case against more than a million rare cases, which is how a benign endometrial result stays a cleared hypothesis rather than an answer, and how the cervical and metastatic explanations stay on the list until something rules them out.
Healz's memory pulls the medical facts out of every upload, dates them, keeps abnormal values up front and connects them across months, so the first episode of bleeding, the hysterectomy years before it and the biopsy that came later sit in one timeline. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Can you get vaginal cancer after a hysterectomy?
Yes. NCI's PDQ treatment summary lists a history of hysterectomy among the risk factors for vaginal cancer, and notes that vaginal carcinoma in situ commonly occurs in the vaginal vault, the surface at the top of the vagina left after the uterus is removed. With no endometrium left to sample, the vaginal walls and the vault are what get examined.
- What does bleeding after menopause usually mean?
Most often it traces to the uterus or the thinned tissue around it, which is why the endometrium is assessed first. When that assessment is normal, the bleeding still has a source, and the remaining candidates include the vaginal wall, the vulva, the cervix, the urethra and the rectum. NCI notes that early vaginal cancer may not cause noticeable signs or symptoms.
- How is vaginal cancer diagnosed?
Through examination and tissue. Colposcopy with biopsy is the diagnostic step, and the American Cancer Society states that a biopsy is the only way to know whether an abnormal finding such as a mass or ulcer is cancer. Imaging then sizes and stages what the biopsy named.
- Is vaginal cancer the same as cervical cancer?
No, though the line between them is drawn by staging rules rather than appearance. NCI states that the AJCC system classifies tumours in the vagina that involve the cervix of women with an intact uterus as cervical cancers, so a tumour that started in the upper vagina and reached the cervix is recorded as cervical. They also share the HPV association.
Bleeding after menopause has one default suspect, and when that suspect is cleared the symptom is still asking its question, so somebody has to keep reading the case rather than file the normal result.
Written by Healz Team · Filed under Health Insights